In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Blood Therapeutics, Inc.

http://www.globalbloodtx.com/index.php

Latest From Global Blood Therapeutics, Inc.

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Deals Financing

Re-Thinking Rare Disease

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Cost Effectiveness Rare Diseases

Accelerated Approval In The US: It Really Is Rare Outside Of Oncology

Everyone knows that cancer drugs dominate use of the Accelerated Approval pathway by the US FDA. But it is remarkable just how rare a non-cancer AA is.

Review Pathway Approvals

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Commercial Deals
See All

Company Information

UsernamePublicRestriction

Register